Lisa Bero
#59,251
Most Influential Person Now
American scientist
Lisa Bero's AcademicInfluence.com Rankings
Lisa Beromedical Degrees
Medical
#765
World Rank
#1006
Historical Rank
#273
USA Rank
Public Health
#177
World Rank
#184
Historical Rank
#54
USA Rank
Download Badge
Medical Chemistry
Lisa Bero's Degrees
- PhD Pharmacy University of California, San Francisco
- Masters Public Health University of California, Berkeley
Why Is Lisa Bero Influential?
(Suggest an Edit or Addition)According to Wikipedia, Lisa Anne Bero, born 1958, is an academic who originally trained in pharmacology and went on to a career studying research integrity and how clinical and basic sciences are translated into clinical practice and health policy. Bero is a Professor of Medicine and Public Health and the Chief Scientist of the Center for Bioethics and Humanities at the University of Colorado. Previously, she had been Chair of Medicines Use and Health Outcomes at the University of Sydney. From 1991 until 2014, she was Professor in the Department of Clinical Pharmacy and in the Institute of Health Policy Studies at the University of California, San Francisco , and is currently an adjunct professor there. She is also Chair of the World Health Organization Essential Medicines Committee, Director of the WHO Collaborating Centre for Pharmaceutical Research and Science Policy, and was Co-Chair of the Cochrane Collaboration from 2013 to 2017. Bero has received multiple awards for her extensive mentoring of high school students to junior faculty.
Lisa Bero's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings (1998) (2260)
- Pharmaceutical industry sponsorship and research outcome and quality: systematic review (2003) (1957)
- Changing Provider Behavior: An Overview of Systematic Reviews of Interventions (2001) (1856)
- Industry sponsorship and research outcome. (2012) (884)
- Coverage by the news media of the benefits and risks of medications. (2000) (521)
- Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. (2014) (468)
- Industry sponsorship and research outcome. (2017) (443)
- Why review articles on the health effects of passive smoking reach different conclusions. (1998) (437)
- Printed educational materials: effects on professional practice and health care outcomes. (2000) (359)
- Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. (2010) (350)
- Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation (2008) (329)
- Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents (2006) (321)
- Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. (2000) (319)
- Systematic reviews of the effectiveness of quality improvement strategies and programmes (2003) (312)
- Outcome reporting in industry-sponsored trials of gabapentin for off-label use. (2009) (306)
- The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. (1995) (306)
- The Quality of Drug Studies Published in Symposium Proceedings (1996) (305)
- Association of journal quality indicators with methodological quality of clinical research articles. (2002) (270)
- Implications of the tobacco industry documents for public health and policy. (2003) (256)
- Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others (2007) (245)
- Influences on the Quality of Published Drug Studies (1996) (236)
- Prevalence of honorary and ghost authorship in Cochrane reviews. (2002) (224)
- Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study (2007) (221)
- Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses (2012) (219)
- The Impact of Clinical Pharmacists' Consultations on Physicians' Geriatric Drug Prescribing: A Randomized Controlled Trial (1992) (208)
- How Consumers and Policymakers Can Use Systematic Reviews for Decision Making (1997) (206)
- Instruments for assessing the quality of drug studies published in the medical literature. (1994) (192)
- GRADE: Assessing the quality of evidence in environmental and occupational health. (2016) (191)
- Measuring the effectiveness of scientific gatekeeping (2014) (187)
- "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. (2008) (182)
- Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. (1996) (175)
- Tobacco industry manipulation of research. (2005) (170)
- Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. (2009) (169)
- ‘Spin’ in published biomedical literature: A methodological systematic review (2017) (168)
- Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. (2001) (159)
- Impact of a Collaborative Care Model on Depression in a Primary Care Setting: A Randomized Controlled Trial (2003) (157)
- Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States (2013) (144)
- EUR-ASSESS Project Subgroup Report on Dissemination and Impact (1997) (141)
- Publication bias and research on passive smoking: comparison of published and unpublished studies. (1998) (140)
- Looking through a keyhole at the tobacco industry. The Brown and Williamson documents. (1995) (135)
- Characterization of Geriatric Drug-Related Hospital Readmissions (1991) (133)
- Challenges in Assessing Mobile Health App Quality: A Systematic Review of Prevalent and Innovative Methods. (2016) (132)
- Instruments for Assessing Risk of Bias and Other Methodological Criteria of Published Animal Studies: A Systematic Review (2013) (129)
- The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. (2013) (127)
- The publication of sponsored symposiums in medical journals. (1992) (126)
- Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? (2007) (125)
- Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. (2002) (125)
- Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews (2016) (125)
- Assessing faculty financial relationships with industry: A case study. (2000) (123)
- DIGITAL CONTACT TRACING TECHNOLOGIES IN EPIDEMICS: A RAPID REVIEW (2020) (122)
- The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review (2018) (119)
- Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals (2006) (116)
- Moral Disengagement in the Corporate World (2009) (115)
- The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures (2018) (114)
- Nicotine and addiction. The Brown and Williamson documents. (1995) (111)
- Evidence based medicine: increasing, not dictating, choice (2007) (109)
- Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan. (2016) (106)
- Tobacco industry denormalisation as a tobacco control intervention: a review (2012) (105)
- Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. (2011) (103)
- Closing the Gap Between Research and Practice: An Overview of Systematic Reviews of Interventions to Promote Implementation of Research Findings by Health Care Professionals (1998) (102)
- Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis (2019) (100)
- Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. (2012) (99)
- Improving the use of research evidence in guideline development: 4. Managing conflicts of interests (2006) (99)
- Environmental tobacco smoke. The Brown and Williamson documents. (1995) (95)
- Why the Cochrane risk of bias tool should include funding source as a standard item. (2013) (92)
- Lawyer control of the tobacco industry's external research program. The Brown and Williamson documents. (1995) (92)
- A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals (2016) (89)
- Industry sponsorship and research outcome: systematic review with meta-analysis (2018) (87)
- How the tobacco industry responded to an influential study of the health effects of secondhand smoke (2002) (85)
- Industry sponsorship and research outcome: a Cochrane review. (2013) (85)
- Why Having a (Nonfinancial) Interest Is Not a Conflict of Interest (2016) (84)
- Financial Conflict‐of‐Interest Policies in Clinical Research: Issues for Clinical Investigators (2003) (83)
- Scientific quality of original research articles on environmental tobacco smoke (1997) (83)
- Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices (2011) (82)
- Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. (2016) (81)
- The advantages and limitations of guideline adaptation frameworks (2018) (81)
- The creation of industry front groups: the tobacco industry and "get government off our back". (2007) (79)
- Print media coverage of research on passive smoking (1999) (79)
- Pathways to independence: towards producing and using trustworthy evidence (2019) (74)
- Characteristics and Impact of Drug Detailing for Gabapentin (2007) (73)
- Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis. (2016) (73)
- Sponsored symposia on environmental tobacco smoke. (1994) (73)
- Retaining Participants in Outpatient and Community-Based Health Studies (2014) (72)
- Barriers and facilitators to the implementation of clinical practice guidelines: A cross-sectional survey among physicians in Estonia (2012) (69)
- Changing Provider Behaviour: An Overview of Systematic Reviews of Interventions to Promote Implementation of Research Findings by Healthcare Professionals (2008) (68)
- The limits of competing interest disclosures. (2005) (66)
- Attitudes of academic and clinical researchers toward financial ties in research: A systematic review (2005) (65)
- Association of trial registration with the results and conclusions of published trials of new oncology drugs (2009) (64)
- Comparison of review articles published in peer-reviewed and throwaway journals. (2002) (64)
- Publication bias and public health policy on environmental tobacco smoke. (1994) (63)
- Addressing Bias and Conflict of Interest Among Biomedical Researchers. (2017) (63)
- Characteristics of materials distributed by drug companies (1996) (63)
- World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. (2016) (62)
- World Health Organization recommendations are often strong based on low confidence in effect estimates. (2014) (60)
- Legislating "sound science": the role of the tobacco industry. (2005) (57)
- Corporate Manipulation of Research: Strategies Are Similar Across Five Industries (2010) (57)
- The IARC Monographs: Updated procedures for modern and transparent evidence synthesis in cancer hazard identification (2019) (56)
- Public Opinions about Overdiagnosis: A National Community Survey (2015) (55)
- WITHDRAWN: Printed educational materials: effects on professional practice and health care outcomes. (2007) (54)
- Lawyer control of internal scientific research to protect against products liability lawsuits. The Brown and Williamson documents. (1995) (52)
- Science in regulatory policy making: case studies in the development of workplace smoking restrictions (2001) (52)
- A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. (2015) (51)
- The cigar revival and the popular press: a content analysis, 1987-1997. (2001) (50)
- Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study (2012) (50)
- Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review (2020) (50)
- Conflicts of Interest in Academic Research: Policies, Processes, and Attitudes (2004) (49)
- Assessing Faculty Financial Relationships With Industry (2000) (49)
- Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. (2003) (49)
- Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores (2018) (49)
- Priority Medicines for Maternal and Child Health: A Global Survey of National Essential Medicines Lists (2012) (48)
- An analysis of methods used to synthesize evidence and grade recommendations in food-based dietary guidelines (2018) (48)
- A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. (2016) (48)
- Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: A review. (2020) (46)
- Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. (2013) (45)
- Nonindustry-Sponsored Preclinical Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-Analysis (2014) (44)
- Getting Research into Practice: Implementing Evidence-Based Practice in Health Care (2000) (44)
- Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons (1986) (44)
- Implementation of financial disclosure policies to manage conflicts of interest. (2004) (43)
- Searching for unpublished data for Cochrane reviews: cross sectional study (2013) (43)
- Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors (2018) (43)
- Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles (2014) (42)
- Tobacco industry response to a risk assessment of environmental tobacco smoke (1993) (42)
- Health care cost effects of public use of a regional poison control center. (1995) (40)
- A review of methods used for hazard identification and risk assessment of environmental hazards. (2019) (40)
- Reporting Science and Conflicts of Interest in the Lay Press (2007) (40)
- Availability, prices and affordability of the World Health Organization’s essential medicines for children in Guatemala (2012) (40)
- Framing Processes in Public Commentary on US Federal Tobacco Control Regulation (2003) (39)
- Private versus public strategies for health service provision for improving health outcomes in resource limited settings: a systematic review. (2011) (39)
- Financial ties and conflicts of interest between pharmaceutical and tobacco companies. (2002) (38)
- Policy makers' perspectives on tobacco control advocates' roles in regulation development (2001) (38)
- Public Participation and Claimsmaking: Evidence Utilization and Divergent Policy Frames in California's Ergonomics Rulemaking (2006) (38)
- A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes (2004) (38)
- Interactions between Non-Physician Clinicians and Industry: A Systematic Review (2013) (38)
- Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: A case study in Zambia (2010) (36)
- Cigars, youth, and the Internet link. (2000) (35)
- GRADE Methods for Guideline Development: Time to Evolve? (2016) (34)
- Tracing the Potential Flow of Consumer Data: A Network Analysis of Prominent Health and Fitness Apps (2017) (34)
- Mental Health Messages in Prominent Mental Health Apps (2018) (34)
- Public Health Chronicles (2005) (34)
- Public health under attack: the American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. (2004) (33)
- The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis. (2016) (33)
- Financial ties between leaders of influential US professional medical associations and industry: cross sectional study (2020) (32)
- Food industry sponsorship of academic research: investigating commercial bias in the research agenda (2018) (32)
- Inappropriate and appropriate selection of 'peers' in grant review. (1994) (32)
- Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals (2009) (32)
- Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review (2020) (32)
- To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008. (2010) (31)
- Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes (2009) (31)
- Implementation plans included in World Health Organisation guidelines (2015) (31)
- Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. (2011) (30)
- Accepting commercial sponsorship (1999) (30)
- The Cycle of Bias in Health Research: A Framework and Toolbox for Critical Appraisal Training (2013) (30)
- Throw it away, Sam: the controlled circulation journals. (1990) (30)
- Availability, prices and affordability of essential medicines in Haiti (2013) (30)
- Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports (2015) (30)
- Reporting of Conflicts of Interest in Meta-Analyses of Trials of Pharmacological Treatments (2011) (29)
- Medicine shortages in Fiji: A qualitative exploration of stakeholders’ views (2017) (29)
- RoB-SPEO: A tool for assessing risk of bias in studies estimating the prevalence of exposure to occupational risk factors from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury (2019) (28)
- Chasing the dollar: why scientists should decline tobacco industry funding (2003) (28)
- Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. (2000) (27)
- A systematic review: Tools for assessing methodological quality of human observational studies (2019) (26)
- Measuring the performance of the Cochrane library. (2012) (26)
- Regulatory agencies hold the key to improving Cochrane reviews of drugs. (2015) (26)
- Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion. (1987) (26)
- Lessons learned from the tobacco industry's efforts to prevent the passage of a workplace smoking regulation. (2000) (26)
- Toward a Healthier Patient Voice: More Independence, Less Industry Funding. (2017) (25)
- Assessing the Appropriateness of Physician Prescribing for Geriatric Outpatients (1993) (25)
- Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity (2016) (24)
- Strategies for obtaining unpublished drug trial data: a qualitative interview study (2013) (24)
- Informatics: Make sense of health data (2015) (24)
- Early ontogeny of κ-opioid receptor regulation of prolactin secretion in the rat (1987) (23)
- Philip Morris International-funded ‘Foundation for a Smoke-Free World’: analysing its claims of independence (2018) (23)
- Barriers and facilitators to the quality use of essential medicines for maternal health in low–resource countries: An Ishikawa framework (2015) (23)
- Factors Associated with Results and Conclusions of Trials of Thiazolidinediones (2009) (23)
- Evaluating Public Commentary and Scientific Evidence Submitted in the Development of a Risk Assessment (2002) (23)
- Assessing faculty financial relationships with industry: a case study (2001) (22)
- Defining Financial Conflicts and Managing Research Relationships: An Analysis of University Conflict of Interest Committee Decisions (2007) (22)
- Conflict of interest as ethical shorthand: Understanding the range and nature of "non-financial conflict of interest" in biomedicine. (2019) (22)
- Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: protocol for a review (2019) (22)
- Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. (2012) (21)
- Assessing the Evidence Submitted in the Development of a Workplace Smoking Regulation: The Case of Maryland (2002) (21)
- Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories (2019) (21)
- Cigar magazines: using tobacco to sell a lifestyle (2001) (21)
- Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study (2019) (20)
- Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. (2011) (20)
- Evidence and argument in policymaking: development of workplace smoking legislation (2009) (20)
- Essential medicines availability is still suboptimal in many countries: a scoping review. (2018) (20)
- Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder (2017) (19)
- Duplicate and salami publication: a prevalence study of journal policies. (2020) (19)
- What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. (2014) (19)
- Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry (2016) (19)
- Developing reliable dietary guidelines (2017) (19)
- Risk Management Policy and Black-Box Warnings (2009) (19)
- Improving researchers’ conflict of interest declarations (2020) (18)
- A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia (2017) (18)
- Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study (2018) (18)
- The "Hot Potato" of Mental Health App Regulation: A Critical Case Study of the Australian Policy Arena (2018) (18)
- Ethical drug marketing criteria for the 21st century (2018) (18)
- Side effects are incompletely reported among systematic reviews in gastroenterology. (2015) (17)
- Conflicts of interest between the sugary food and beverage industry and dental research organisations: time for reform (2019) (17)
- Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009-2017). (2019) (17)
- The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics. (2013) (16)
- Implementation of a workplace smoking ban in bars: The limits of local discretion (2008) (16)
- Equity, Accountability, Transparency: Implementation of the Contributorship Concept in a Multi-site Study (2005) (16)
- Tobacco industry sponsorship of a book and conflict of interest. (2006) (16)
- The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. (2006) (16)
- Tobacco interests or the public interest: 20 years of industry strategies to undermine airline smoking restrictions (2006) (15)
- CONSORT 2010. Authors' reply (2010) (15)
- Making nutrition guidelines fit for purpose (2019) (15)
- Role of serotonin in opiate-induced prolactin secretion and antinociception in the developing rat. (1987) (15)
- Commercial interests, transparency, and independence: a call for submissions (2019) (15)
- Applying the essential medicines concept to US preferred drug lists. (2011) (15)
- The Inclusion of Nurses in Pharmaceutical Industry-Sponsored Events: Guess Who Is Also Coming to Dinner? (2016) (15)
- Review of the quality of pediatric medications in developing countries. (2013) (14)
- The SSSPIN study—spin in studies of spin: meta-research analysis (2019) (14)
- Disclosure policies for gifts from industry to academic faculty. (1998) (14)
- The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. (2013) (14)
- The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta‐analysis (2014) (14)
- Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year (2014) (14)
- Creating effective interrupted time series graphs: Review and recommendations (2020) (14)
- Systematic Review: A Method at Risk for Being Corrupted (2017) (14)
- “Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study (2019) (14)
- The electronic future: What might an online scientific paper look like in five years' time? (1997) (14)
- Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations. (2020) (13)
- High School Journalists' Perspectives on Tobacco (2002) (13)
- Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation (2021) (13)
- How can the integrity of occupational and environmental health research be maintained in the presence of conflicting interests? (2019) (13)
- Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis (2015) (13)
- Critical appraisal training increases understanding and confidence and enhances the use of evidence in diverse categories of learners (2015) (12)
- Commercial influence and covid-19 (2020) (12)
- Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis (2020) (12)
- Association of industry ties with outcomes of studies examining the effect of wholegrain foods on cardiovascular disease and mortality: systematic review and meta-analysis (2019) (12)
- Evaluating Systematic Reviews and Meta-Analyses (2006) (12)
- Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality (2018) (12)
- Perinatal effects of drugs of abuse. (1987) (11)
- A call to action to reshape evidence synthesis and use for nutrition policy. (2016) (11)
- A clearer view of evidence in treating macular degeneration: off-label policies and independent research. (2014) (11)
- Industry Front Groups: A Tobacco Case Study (2007) (10)
- The role of public participation in public health initiatives: An analysis of the WHO Framework Convention on Tobacco Control (2010) (10)
- The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. (2015) (10)
- The ties that bind (2017) (10)
- Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study (2019) (10)
- Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. (2009) (10)
- Commercialization of User Data by Developers of Medicines-Related Apps: a Content Analysis (2019) (10)
- Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. (1987) (10)
- Managing financial conflicts of interest in research. (2005) (10)
- "A delicate diplomatic situation": tobacco industry efforts to gain control of the Framingham Study. (2010) (10)
- Cochrane Sustainable Healthcare: evidence for action on too much medicine. (2019) (10)
- Conduct and reporting of formula milk trials: systematic review (2021) (10)
- Assessment of the Methods Used to Develop Vitamin D and Calcium Recommendations—A Systematic Review of Bone Health Guidelines (2021) (9)
- Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody. (1988) (9)
- Interest Groups, Lobbying, and Deception: The Tobacco Industry and Airline Smoking (2007) (9)
- Methods used to meta-analyse results from interrupted time series studies: A methodological systematic review protocol. (2020) (9)
- Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies. (2011) (9)
- Ten tips for spotting industry involvement in science policy (2018) (9)
- "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise. (2008) (9)
- A Social Network Analysis of the Financial Links Backing Health and Fitness Apps (2017) (9)
- Conflicts of interest and recommendations in clinical guidelines, opinion pieces, and narrative reviews (2019) (9)
- Catecholaminergic regulation of opiate-stimulated growth hormone secretion in the developing rat. (1986) (9)
- Improving the use of information in medical effectiveness research. (1996) (9)
- The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. (2005) (9)
- Producing Independent, Systematic Review Evidence: Cochrane's Response to COVID-19. (2020) (9)
- Medicaid drug selection committees and inadequate management of conflicts of interest. (2013) (8)
- Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009 (2020) (8)
- “The Tobacco Products Research Trust 1982–1996” (1998) (8)
- Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. (2020) (7)
- Systematic Reviews: Perhaps “The Answer to Policy Makers’ Prayers”? (2014) (7)
- Quantitative determination of 5-hydroxytryptophan in dissected brain regions by on-line trace enrichment HPLC with electrochemical detection. (1984) (7)
- GPs' prescribing behaviour may be affected by drug promotion (1996) (7)
- Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians. (2019) (7)
- Investigation of Risk Of Bias due to Unreported and SelecTively included results in meta-analyses of nutrition research: the ROBUST study protocol. (2019) (7)
- Interpretation and use of evidence in state policymaking: a qualitative analysis (2017) (7)
- Participation and argument in legislative debate on statewide smoking restrictions (2007) (7)
- Study sponsorship and the nutrition research agenda: analysis of cohort studies examining the association between nutrition and obesity (2017) (7)
- Comparison of methodological quality between the 2007 and 2019 Canadian dietary guidelines (2020) (7)
- Industry payments to Australian medical oncologists and clinical haematologists: a cross‐sectional analysis of publicly available disclosures (2020) (6)
- Policy makers must act on incomplete evidence in responding to COVID-19. (2020) (6)
- Bias related to funding source in statin trials (2014) (6)
- Toolkit for detecting misused epidemiological methods (2021) (6)
- The politics of smoking in federal buildings: an executive order case study. (2009) (6)
- Getting the systematic review basics right helps clinical practice: 4 common pitfalls for systematic review authors to avoid (2017) (6)
- Expensive medicines: ensuring objective appraisal and equitable access (2015) (6)
- Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States (2016) (6)
- Methodological quality of public health guideline recommendations on vitamin D and calcium : a systematic review protocol (2019) (6)
- Journalists and conflicts of interest in science: beliefs and practices (2009) (6)
- Meta-research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust (2018) (6)
- A comparison of policy provisions for managing “financial” and “non-financial” interests across health-related research organizations: A qualitative content analysis (2020) (6)
- Not All Influences on Science Are Conflicts of Interest. (2018) (5)
- Systematic Reviews Should Consider Effects From Both the Population and the Individual Perspective. (2021) (5)
- The publication of commercially supported supplements statement. (1995) (5)
- Evidence based medicine: looking forward and building on what we have learnt (2014) (5)
- Achieving greater independence from commercial influence in research (2021) (5)
- Association between personal conflicts of interest and recommendations on medical interventions (2013) (5)
- Experts identified warning signs of fraudulent research: a qualitative study to inform a screening tool. (2022) (5)
- Healthcare outcomes assessed with non‐experimental designs compared with those assessed in randomised trials (2012) (5)
- CONSORT 2010 (2010) (5)
- Conrad and Becker’s “10 Criteria” Fall Short of Addressing Conflicts of Interest in Chemical Safety Studies (2011) (5)
- “There are ways … drug companies will get into DTC decisions”: How Australian drug and therapeutics committees address pharmaceutical industry influence (2020) (5)
- Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors (2018) (4)
- Interpreting evidence in general practice: Bias and conflicts of interest. (2018) (4)
- On WHO’s essential medicines process and transparency (2014) (4)
- "The lesser of two evils": a framework analysis of consumers' perspectives on opioid deprescribing and the development of opioid deprescribing guidelines. (2021) (4)
- Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study (2020) (4)
- Challenges to generating evidence-informed policy and the role of systematic reviews and (perceived) conflicts of interest (2016) (4)
- Identifying Carcinogens: The Tobacco Industry and Regulatory Politics in the United States (2006) (4)
- National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. (2016) (4)
- When beauty is but skin deep: dealing with problematic studies in systematic reviews. (2021) (4)
- Investigation of Risk Of Bias due to Unreported and SelecTively included results in meta-analyses of nutrition research: the ROBUST study protocol (2019) (4)
- Making systematic reviews global. (2011) (4)
- Conflicts of Interest in Nutrition Research. (2018) (3)
- ‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders (2021) (3)
- Dear doctor ... regarding calcium channel blockers. (1996) (3)
- Assessing the quality of evidence in studies estimating prevalence of exposure to occupational risk factors: The QoE-SPEO approach applied in the systematic reviews from the WHO/ILO Joint Estimates of the Work-related burden of disease and Injury (2022) (3)
- Association of food industry ties with findings of studies examining the effect of dairy food intake on cardiovascular disease and mortality: systematic review and meta-analysis (2020) (3)
- Improving the Quality of Systematic Reviews in Public Health: Introduction to the Series. (2020) (3)
- Increasing, not dictating, choice (2007) (3)
- Philip Morris involvement in the development of an air quality laboratory in El Salvador (2009) (3)
- Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors (2010) (3)
- Instruments for Assessing Risk of Bias and Other Methodological Criteria: Krauth et al. Respond (2014) (3)
- Association Between Conflicts of Interest and Authors’ Positions on Harms of Varenicline: a Cross-Sectional Analysis (2021) (3)
- Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare (2020) (3)
- Stamp out fake clinical data by working together (2022) (3)
- Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis (2022) (3)
- Health promoter, advocate, legitimiser — the many roles of WHO guidelines: a qualitative study (2019) (2)
- Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme (2010) (2)
- Endocrine consequences of perinatal methadone exposure. (1987) (2)
- Towards a framework for systematic reviews of the prevalence of exposure to environmental and occupational risk factors (2022) (2)
- Using interactive data visualization to facilitate user selection and comparison of risk of bias tools for observational studies of exposures. (2020) (2)
- Comparison of preprints with peer-reviewed publications on COVID-19: Discrepancies in results reporting and conclusions (2020) (2)
- The Tobacco Industry and the Data Quality Act (2007) (2)
- Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review (2021) (2)
- Understanding professional stakeholders' active resistance to guideline implementation: The case of Canadian breast screening guidelines. (2020) (2)
- Risky business? Pharmaceutical industry sponsorship of health consumer groups (2021) (2)
- Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. (2007) (2)
- Clinical trial registration at Tobacco Control (2006) (2)
- "It’s Not Smooth Sailing": Bridging the Gap Between Methods and Content Expertise in Public Health Guideline Development (2020) (2)
- Making the cigar news (2000) (2)
- Managing risk from conflicts of interest in guideline development committees (2022) (2)
- The Cochrane Library Oversight Committee. (2011) (2)
- Comparison of preprints and final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in interpretation (2021) (2)
- Response to Acquavella J, conflict of interest: a hazard for epidemiology. (2019) (2)
- Global access to affordable direct oral anticoagulants (2021) (2)
- 'Somebody Might Actually Make Up Data': An Empirical Qualitative Study on How to Screen for Fake Research (2022) (2)
- Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study (2021) (2)
- Variations in processes for guideline adaptation: a qualitative study of World Health Organization staff experiences in implementing guidelines (2020) (2)
- Pharmaceutical industry payments to Australian healthcare professionals (October 2015 to October 2018) (2019) (1)
- Disclosure of funding sources and conflicts of interest in evidence underpinning vitamin D and calcium recommendations in bone health guidelines (2022) (1)
- Strengthening the incentives for responsible research practices in Australian health and medical research funding (2021) (1)
- Pharmaceutical industry payments to healthcare professionals (May 2016-Apr 2017) (2019) (1)
- Creating a text data-mining application for use in public health informatics (2004) (1)
- "Educational" advertisements--I haven't seen one yet! (2001) (1)
- A critical review of methodologies used in pharmaceutical pricing policy analyses. (2022) (1)
- Methods used to meta-analyse results from interrupted time series studies: A methodological systematic review protocol (2020) (1)
- Term limits and the tobacco industry. (2014) (1)
- Methods used to meta-analyse results from interrupted time series studies: A methodological systematic review protocol. (2020) (1)
- Methods used to select results to include in meta-analyses of nutrition research: a meta-research study. (2021) (1)
- Value and Challenges of Using Observational Studies in Systematic Reviews of Public Health Interventions. (2022) (1)
- Application of the Navigation Guide Systematic Review Methodology to Assessing the Potential Developmental and Reproductive Hazards of Triclosan (2014) (1)
- Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study (2022) (1)
- The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system (2019) (1)
- Private food safety standards in the global food supply chain: a scoping review protocol. (2019) (1)
- The Criticism Management System for the Cochrane Library (2002) (1)
- Mechanisms for addressing the influence of corporations on public health (2021) (1)
- Tobacco Interests or the Public Interests: Twenty-years of Tobacco Industry Strategies to Undermine Airline Smoking Restrictions (2006) (1)
- Methods used to select results to include in meta-analyses of nutrition research: a meta-research study (2021) (1)
- Development of the Navigation Guide Evidence-to-Decision Framework for Environmental Health (2022) (0)
- Author's response to reviews Title:Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis Authors: (2015) (0)
- Mo1105 Side Effects Are Side Issues: Completeness of Reporting of Harms Among Systematic Reviews in Gastroenterology (2014) (0)
- Protocol - Private vs. public strategies for health service provision for improving health in resource-limited settings. (2010) (0)
- Power to the people! (1986) (0)
- Response to Toshihide Tsuda, Yumiko Miyano and Eiji Yamamoto [1] (2022) (0)
- Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions (2022) (0)
- Thanks to Reviewers2014 (2014) (0)
- Abstracts from the Collegium Ramazzini (2019) (0)
- How food nutrition companies shape the nutrition research agenda (2018) (0)
- Advancing Science in the Service of Humanity Professionalism and Ethical Safeguards (2016) (0)
- The tension between national consistency and jurisdictional professional expansion: The case of pharmacist-administered vaccinations (2022) (0)
- Abstract 8489: Study Modifications & Primary Endpoint Reinterpretations Prior to Food & Drug Administration Approval of High-Risk Cardiovascular Devices (2011) (0)
- [Shall we ban industrial funds for research?]. (2007) (0)
- ThePoliticsofSmokinginFederalBuildings:AnExecutive OrderCaseStudy (2009) (0)
- 075 The Use of GRADE Methods in the World Health Organization (Who) Public Health Guidelines (PHG): Distribution of Strength of Recommendations and Confidence in Estimates of Effect (2013) (0)
- “Never waste a good crisis”: Opportunities and constraints from the COVID-19 pandemic on pharmacists’ scope of practice (2022) (0)
- Correction: Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation (2009) (0)
- Big Pharma (The Play) (2007) (0)
- Animal Studies : A Systematic Review (0)
- Thanks to Reviewers2003 (2003) (0)
- Policies affecting the supply and access of opioid analgesics: a scoping review protocol. (2020) (0)
- Adjudicated dataset for “Spin” in published biomedical literature: A methodological systematic review (2017) (0)
- THANKS TO REVIEWERS1999 (1999) (0)
- Pharmaceutical industry funding of events for Australian healthcare professionals (October 2015 to October 2018) (2019) (0)
- Response to Soares et al. (2019) (0)
- Methodological quality of recommendations on vitamin D and calcium-a systematic review of bone health guidelines (2021) (0)
- Policies affecting the supply and access of opioid analgesics: a scoping review protocol. (2020) (0)
- Proposed methods for evaluating efforts made by governments to prevent and mitigate corporate influence and conflicts of interest in public health policy (2022) (0)
- SPECIAL ARTICLES Equity, Accountability, Transparency: Implementation of the Contributorship Concept in a Multi-site Study (2005) (0)
- Correction: Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews (2020) (0)
- Are the Peers Peers?-Reply (1995) (0)
- Relationships Between Pharmaceutical and Tobacco Companies (2002) (0)
- Public opinions about overdiagnosis: A national community survey [dataset] (2015) (0)
- IADR and AADR applaud the Lancet Oral Health Series – Authors' reply (2020) (0)
- 19 Pharmaceutical industry payments to thought leaders in cardiovascular disease and diabetes (2019) (0)
- Corrigendum to "Term limits and the tobacco industry" [Social Sci. & Med. 104 (2014) 1-5] (2014) (0)
- INCLUSION OF ROLL-IN PATIENTS IN PRE-FDA APPROVAL CARDIOVASCULAR DEVICE TRIALS (2010) (0)
- Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review (2021) (0)
- Making the Cigar News - eScholarship (2000) (0)
- Pharmaceutical Company Sponsorship of Research : A Review (2006) (0)
- Health CareCostEffects ofPublic Useofa Regional Poison Control Center (1995) (0)
- Patient-targeted interventions for opioid deprescribing: An overview of systematic reviews. (2023) (0)
- Author's response to reviews Title: Association of Trial Registration with the Results and Conclusions of Published Trials of New Oncology Drugs Authors: (2009) (0)
- ARE THE PEERS PEERS ? AUTHORS' REPLY (1995) (0)
- Social Scientists and the Human Terrain System (HTS) Project (2013) (0)
- Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections (2015) (0)
- Clarification of study and citation. (2007) (0)
- Where is your data going (2019) (0)
- secondhand smoke influential study of the health effects of How the tobacco industry responded to an (2005) (0)
- Relationships between pharmaceutical and Tobacco Companies. Author's reply (2002) (0)
- 59 Perspectives of deprescribing experts on opioid overtreatment in australia: a focus group study (2019) (0)
- Strengthening the incentives for responsible research practices in Australian health and medical research funding (2021) (0)
- Title Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan Permalink (2016) (0)
- Open letter to EU Commission about proposed EDC Criteria (2016) (0)
- Misleading the public about secondhand smoke ... Again (2019) (0)
- Methods for evaluating efforts made by governments to prevent and mitigate corporate influence and conflicts of interest in public health policy (2022) (0)
- The Promotion of Gabapentin (2007) (0)
- THE PUBLICATION OF COMMERCIALLY SUPPORTED SUPPLEMENTS STATEMENT. AUTHORS' REPLY (1995) (0)
- Thanks to Reviewers2000 (2000) (0)
- Correction: Odds ratios should be avoided when events are common (British Medical Journal (1998) 317 (1318)) (1998) (0)
- The Role of Conflicts of Interest in Developing Popular Understanding of Public Health Risks and the Desire for Political Change (2010) (0)
- Author's response to reviews Title:Conflicts of Interest and Critiques of the use of Systematic Reviews in Policymaking: An Analysis of Opinion Articles Authors: (2014) (0)
- Correction: Toolkit for detecting misused epidemiological methods (2022) (0)
- Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. (2015) (0)
- Understanding the Dynamics of More Restrictive Medicines Policy: A Case Study of Codeine Up-Scheduling in Australia (2022) (0)
- AJPH202033097_Verbeek 820..825 (2021) (0)
- What Contributes to the Variation of Dairy Recommendations in Global Food-Based Dietary Guidelines (2021) (0)
- The Devil they knew: chemical documents analysis of industry influence on PFAS Science (2022) (0)
- ISEE principles for evidence synthesis and evaluation in environmental health (2021) (0)
- SHORT ORAL PRESENTATIONS 36..36 (2013) (0)
- Evolution of Industry-Academia Relationships in Development of Orthopaedic Implants (2011) (0)
- A comparative analysis of the roles and use of evidence in pharmacy policy in Australia (2022) (0)
- Information and promotional strategies by pharmaceutical companies for clinicians (2019) (0)
- Investigation of bias due to selective inclusion of study effect estimates in meta-analyses of nutrition research (2022) (0)
- A sorry tale of unnecessary secrecy about medicine safety (2021) (0)
- Branded Care: The Policy Implications of Pharmaceutical Industry-Funded Nursing Care Related to Specialty Medicines (2022) (0)
- Reducing commercial influence over guidelines won’t fix poverty but is still worth striving for (2023) (0)
This paper list is powered by the following services:
Other Resources About Lisa Bero
What Schools Are Affiliated With Lisa Bero?
Lisa Bero is affiliated with the following schools:
